Scarica l'app Stockscreener
1.59
4.61%
0.07
Dopo l'orario di chiusura:
1.59
Precedente Chiudi:
$1.52
Aprire:
$1.51
Volume 24 ore:
539.37K
Relative Volume:
0.22
Capitalizzazione di mercato:
$85.00M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-1.1439
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
+14.39%
1M Prestazione:
+29.27%
6M Prestazione:
-20.10%
1 anno Prestazione:
+1.92%
Intervallo 1D:
$1.51
$1.595
Intervallo di 1 settimana:
$1.36
$1.595
Portata 52W:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Confronta MIST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.59 | 74.32M | 0 | -59.69M | -46.54M | -1.39 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Millennium Management LLC - Defense World
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Manila Times
Milestone Pharmaceuticals Executives Set for Key Presentation at Jefferies Healthcare Conference - Stock Titan
Analysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $17.00 - Defense World
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why - Yahoo Finance
Cubist Systematic Strategies LLC Takes $73,000 Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Milestone Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Milestone Pharmaceuticals Reports First Quarter 2025 Financial R - GuruFocus
Milestone Pharmaceuticals Navigates Regulatory Challenges and Financial Updates in Q1 2025 - TipRanks
Milestone Pharmaceuticals (MIST) Aims to Resolve FDA Issues for CARDAMYST | MIST Stock News - GuruFocus
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results - marketscreener.com
Milestone Pharmaceuticals reports Q1 EPS (31c) vs (21c) last year - TipRanks
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone's CARDAMYST Gets FDA Path Forward: Manufacturing Issues Only, $56M Cash Runway Revealed - Stock Titan
Milestone Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - GlobeNewswire
Milestone Pharmaceuticals (MIST) Expected to Announce Earnings on Monday - Defense World
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - News Heater
MIST’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
What is Milestone Pharmaceuticals Inc (MIST) Stock Return on Shareholders’ Capital? - Sete News
Deeper Dive: Understanding Milestone Pharmaceuticals Inc (MIST) Through its Various Ratios - DWinneX
Stock Market Recap: Milestone Pharmaceuticals Inc (MIST) Concludes at 0.88, a -60.89 Surge/Decline - DWinneX
The Attractiveness of Investing In Milestone Pharmaceuticals Inc (MIST) is Growing - knoxdaily.com
Milestone Pharmaceuticals Inc (MIST)’s stock price range in the last year - uspostnews.com
Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News
Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX
Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com
A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com
Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com
Examining Milestone Pharmaceuticals Inc (MIST) stock is warranted - uspostnews.com
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha
Research Analysts Set Expectations for MIST Q1 Earnings - Defense World
MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com Canada
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - MSN
MIST stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa
HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks
TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy - MarketScreener
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):